Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain

Today the evaluation of unwanted immunogenicity is a key component in the clinical safety evaluation of new biotherapeutic drugs and macromolecular delivery strategies. However, the evolving structural complexity in contemporary biotherapeutics creates a need for on-going innovation in assay designs...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Derrick, Simmons, Erica, Abdeen, Sanofar, Kinne, Adam, Parmer, Elijah, Rinker, Sherri, Thystrup, Jennifer, Ramaswamy, Swarna, Bowsher, Ronald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322160/
https://www.ncbi.nlm.nih.gov/pubmed/34326436
http://dx.doi.org/10.1038/s41598-021-95055-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322160/
https://www.ncbi.nlm.nih.gov/pubmed/34326436
http://dx.doi.org/10.1038/s41598-021-95055-x

Ejemplares similares